Future prospects of EGFR-TKIs and surgery for non-small-cell lung cancer

被引：0
|
作者：
Nagano, Tatsuya [1 ]
Tachihara, Motoko [1 ]
Tanaka, Yugo [2 ]
机构：
[1] Kobe Univ, Dept Internal Med, Div Resp Med, Grad Sch Med, Kobe, Hyogo, Japan
[2] Kobe Univ, Div Thorac Surg, Grad Sch Med, Kobe, Hyogo, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2022年 / 14卷 / 04期
关键词：
OSIMERTINIB;
D O I：
10.21037/jtd-22-57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：809 / 811
页数：3
相关论文
共 50 条
  • [31] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [32] Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials
    Zhao, Pengfei
    Zhen, Hongchao
    Zhao, Hong
    Zhao, Lei
    Cao, Bangwei
    BMC CANCER, 2022, 22 (01)
  • [33] Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
    Liu, Yang
    Sun, Li
    Xiong, Zhi-Cheng
    Sun, Xin
    Zhang, Shu-Ling
    Ma, Jie-Tao
    Han, Cheng-Bo
    ONCOTARGETS AND THERAPY, 2017, 10 : 2267 - 2279
  • [34] The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them
    Rocco, Danilo
    Della Gravara, Luigi
    Palazzolo, Giovanni
    Gridelli, Cesare
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 1016 - 1024
  • [35] EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis
    Thang Thanh Phan
    Vinh Thanh Tran
    Bich-Thu Tran
    Toan Trong Ho
    Suong Phuoc Pho
    Anh Tuan Le
    Vu Thuong Le
    Hang Thuy Nguyen
    Son Truong Nguyen
    CANCER REPORTS, 2022, 5 (08)
  • [36] EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
    Wenfeng Fang
    Yihua Huang
    Shaodong Hong
    Zhonghan Zhang
    Minghui Wang
    Jiadi Gan
    Wenjing Wang
    Honglin Guo
    Kai Wang
    Li Zhang
    BMC Cancer, 19
  • [37] Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer
    Jassem, Jacek
    Dziadziuszko, Rafal
    LANCET RESPIRATORY MEDICINE, 2020, 8 (06) : 528 - 529
  • [38] EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
    Fang, Wenfeng
    Huang, Yihua
    Hong, Shaodong
    Zhang, Zhonghan
    Wang, Minghui
    Gan, Jiadi
    Wang, Wenjing
    Guo, Honglin
    Wang, Kai
    Zhang, Li
    BMC CANCER, 2019, 19 (1)
  • [39] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
    Carlisle, Jennifer W.
    Ramalingam, Suresh S.
    FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
  • [40] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    PHARMACOLOGICAL RESEARCH, 2021, 170
12345